

DAFTAR PUSTAKA

- Acosta PE. “Antiviral agents (nonretroviral)”, In: *Brunton LL, Hilal-Dandan R, Knollmann BJ, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics 13th ed.* New York: McGraw-Hill Education. 2018. p. 1105–16.
- Agrawal, U., Raju, R., dan Udwardia, Z.F., 2020. Favipiravir: A new and emerging antiviral option in COVID-19. *Medical Journal Armed Forces India*, **76**: 370–376.
- Al-Abdouh, A., Bizanti, A., Barbarawi, M., Jabri, A., Kumar, A., Fashanu, O.E., dkk., 2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. *Contemporary Clinical Trials*, **101**: 106272.
- Al-Muhsen, S., Al-Numair, N.S., Saheb Sharif-Askari, N., Basamh, R., Alyounes, B., Jabaan, A., dkk., 2022. Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. *Frontiers in Medicine*, **9**: 826247.
- Amirian, E.S. dan Levy, J.K., 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. *One Health*, **9**: 100128.
- Anderson, M.R., Bach, P.B., dan Baldwin, M.R., 2021. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value. *Pharmacoeconomics - Open*, **5**: 129–131.
- Angamo, M.T., Mohammed, M.A., dan Peterson, G.M., 2021. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. *Infection*, .
- Ara Perveen, R., Nasir, M., Murshed M, M., Naznin, R., dan Ahmed, S.N., 2021a. Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 patients: A Cross Sectional Observation in Bangladesh. *International Journal of Medical Science and Clinical Invention*, **8**: 5196–5201.
- Ara Perveen, R., Nasir, M., Murshed M, M., Naznin, R., dan Ahmed, S.N., 2021b. Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 patients: A Cross Sectional Observation in Bangladesh. *International Journal of Medical Science and Clinical Invention*, **8**: 5196–5201.
- Bae, J.H., Choe, H.J., Holick, M.F., dan Lim, S., 2022. Association of vitamin D status with COVID-19 and its severity: Vitamin D and COVID-19: a narrative review. *Reviews in Endocrine and Metabolic Disorders*, **23**: 579–599.
- Bansal, V., Mahapure, K.S., Bhurwal, A., Gupta, I., Hassanain, S., Makadia, J., dkk., 2021. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. *Frontiers in Medicine*, **7**: 606429.
- Bennasrallah, C., Zemni, I., Dhouib, W., Sriha, H., Mezhoud, N., Bouslama, S., dkk., 2021. Factors associated with a prolonged negative conversion of viral

- RNA in patients with COVID-19. *International Journal of Infectious Diseases*, **105**: 463–469.
- Bohn, M.K., Lippi, G., Horvath, A., Sethi, S., Koch, D., Ferrari, M., dkk., 2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. *Clinical Chemistry and Laboratory Medicine (CCLM)*, **58**: 1037–1052.
- Bouman, A., Heineman, M.J., dan Faas, M.M., 2005. Sex hormones and the immune response in humans. *Human Reproduction Update*, **11**: 411–423.
- Brown, A.J., Won, J.J., Graham, R.L., Dinnon, K.H., Sims, A.C., Feng, J.Y., dkk., 2019. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Research*, **169**: 104541.
- Buetti, N., Trimboli, P., Mazzuchelli, T., Lo Priore, E., Balmelli, C., Trkola, A., dkk., 2020. Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients. *Endocrine*, **70**: 454–460.
- Cai, Qingxian, Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., dkk., 2020. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*, **6**: 1192–1198.
- Cao, Y., Deng, Q., dan Dai, S., 2020. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. *Travel Medicine and Infectious Disease*, **35**: 101647.
- Cascella, M., Rajnik, M., Coumo, A., Dulebohn, S.C., dan Di Napoli, R., 2021. Evaluation, and Treatment of Coronavirus (COVID-19), (2021). *StarPeals*.
- Cen, Y., Chen, X., Shen, Y., Zhang, X.-H., Lei, Y., Xu, C., dkk., 2020. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study. *Clinical Microbiology and Infection*, **26**: 1242–1247.
- Chan, J.F.-W., Yuan, S., Kok, K.-H., To, K.K.-W., Chu, H., Yang, J., dkk., 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*, **395**: 514–523.
- Chen, C., Zhang, Yi, Huang, J., Yin, P., Cheng, Z., Wu, J., dkk., 2020. 'Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial', , *preprint*, . *Infectious Diseases (except HIV/AIDS)*.
- Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., dkk., 2020. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International*, **97**: 829–838.
- Cui, S., Chen, S., Li, X., Liu, S., dan Wang, F., 2020. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, **18**: 1421–1424.
- Cui, Y., Sun, Y., Sun, J., Liang, H., Ding, X., Sun, X., dkk., 2021. Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. *Infectious Diseases and Therapy*, **10**: 2447–2463.

- Dabbous, H.M., Abd-Elsalam, S., El-Sayed, M.H., Sherief, A.F., Ebeid, F.F.S., El Ghafar, M.S.A., dkk., 2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. *Archives of Virology*, **166**: 949–954.
- Damayanti, H., Sajinadiyasa, I.G.K., Risni, H.W., dan Sauriasari, R., 2021. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. *Kesmas: National Public Health Journal*, **16**: .
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbutto, V., Veronese, N., dkk., 2020. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. *International Journal of Environmental Research and Public Health*, **17**: 2690.
- Diallo, A., Carlos-Bolumbu, M., Traoré, M., Diallo, M.H., dan Jedrecy, C., 2021. An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease. *Journal of Public Health Research*, **10**: .
- Donsu, Y.C. dan Hasmono, D., 2020. Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19) Review of Azithromycin for Coronavirus Disease 2019 (COVID-19). . e, **17**: 15.
- E Tanni¹, S., Silvinato², A., Floriano³, I., A Bacha⁴, H., Naime Barbosa⁵, A., dan M Bernardo⁶, W., 2022. Use of remdesivir in patients with COVID-19: a systematic review and meta-analysis. *Jornal Brasileiro de Pneumologia*, e20210393.
- Fan, Z., Chen, L., Li, J., Cheng, X., Yang, J., Tian, C., dkk., 2020. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clinical Gastroenterology and Hepatology*, **18**: 1561–1566.
- Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., dan Harapan, H., 2021. Antivirals for COVID-19: A critical review. *Clinical Epidemiology and Global Health*, **9**: 90–98.
- Fu, Y., Han, P., Zhu, R., Bai, T., Yi, J., Zhao, X., dkk., 2020. Risk factors for viral RNA shedding in COVID-19 patients. *European Respiratory Journal*, **56**: 2001190.
- Furuta, Y., Komeno, T., dan Nakamura, T., 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. *Proceedings of the Japan Academy, Series B*, **93**: 449–463.
- Garibaldi, B.T., Wang, K., Robinson, M.L., Zeger, S.L., Bandeen-Roche, K., Wang, M.-C., dkk., 2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA Network Open*, **4**: e213071.
- Gorbalenya, A., n.d. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group 20.
- Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., dkk., 2020. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *New England Journal of Medicine*, **382**: 2327–2336.
- Guan, W., Ni, Z., Hu, Yu, Liang, W., Ou, C., He, J., dkk., 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine*, **382**: 1708–1720.

- Guo, A., Lu, J., Tan, H., Kuang, Z., Luo, Y., Yang, T., dkk., 2021. Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. *Scientific Reports*, **11**: 7310.
- Gupte, V., Hegde, R., Sawant, S., Kalathingal, K., Jadhav, S., Malabade, R., dkk., 2022. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. *BMC Infectious Diseases*, **22**: 1.
- Hakamifard, A., Soltani, R., Maghsoudi, A., Rismanbaf, A., Aalinezhad, M., Tarrahi, J., dkk., 2022. The effect of vitamin E and vitamin C in patients with COVID-19 pneumonia; a randomized controlled clinical trial **8**: 6.
- Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., dan Martinez-de-Hoyo, R., 2021. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Scientific Reports*, **11**: 11022.
- Hirai, N., Nishioka, Y., Sekine, T., Nishihara, Y., Okuda, N., Nishimura, T., dkk., 2021. Factors associated with viral clearance periods from patients with COVID-19: A retrospective observational cohort study. *Journal of Infection and Chemotherapy*, **27**: 864–868.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., dkk., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, **395**: 497–506.
- Instiaty, Darmayani, I.G.A.A.P.S., Marzuki, J.E., Angelia, F., William, Siane, A., dkk., 2020. Antiviral treatment of COVID-19: a clinical pharmacology narrative review. *Medical Journal of Indonesia*, **29**: 332–45.
- Ippolito, M. dan Cortegiani, A., 2021. Length of remdesivir treatment in patients with severe COVID-19. *Breathe*, **17**: 200276.
- Joshi, S., Vora, A., Venugopal, K., Dadhich, P., Daxini, A., Bhagat, S., dkk., 2022. Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India. *Pragmatic and Observational Research*, **Volume 13**: 33–41.
- Kelana, A.I., Ikawati, Z., dan Wiedyaningsih, C., 2021. Clinical Characteristic and Antibiotic Patterns among Coronavirus Disease 2019 In-patient Wava Husada Hospital Malang. *Indonesian Journal of Clinical Pharmacy*, **10**: 321–329.
- Kumar, M. dan Al Khodor, S., 2020. Pathophysiology and treatment strategies for COVID-19. *Journal of Translational Medicine*, **18**: 353.
- Lee, S., Santarelli, A., Caine, K., Schritter, S., Dietrich, T., dan Ashurst, J., 2020. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience. *Journal of Osteopathic Medicine*, **120**: 926–933.
- Lemeshow, S., Hosmer, Jr.D.W., Klar, J., dan Lwanga, S., 1990. Adequacy of Sample Size in Health Studies. *Published on behalf of the World Health Organization by Wiley*, .
- Lestari, A.A.W., n.d. Resistensi Insulin : Definisi, Mekanisme dan Pemeriksaan Laboratoriumnya 8.

- Levani, Y., Prastya, A.D., dan Mawaddatunnadila, S., 2021. Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi **17**: 14.
- Lexicomp, 2022. 'Login', . URL: <https://online.lexi.com/lco/action/home> (diakses tanggal 22/8/2022).
- Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., dkk., 2020. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology*, **109**: 531–538.
- Li, L., Wang, X., Wang, R., Hu, Y., Jiang, S., dan Lu, X., 2020. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. *Drug Design, Development and Therapy*, **Volume 14**: 3001–3013.
- Li, X., Zhong, X., Wang, Y., Zeng, X., Luo, T., dan Liu, Q., 2021. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLOS ONE*, **16**: e0250602.
- Lin, H.X.J., Cho, S., Meyyur Aravamudan, V., Sanda, H.Y., Palraj, R., Molton, J.S., dkk., 2021. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. *Infection*, **49**: 401–410.
- Liu, K., Chen, Y., Lin, R., dan Han, K., 2020. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *Journal of Infection*, **80**: e14–e18.
- Lou, L., Zhang, H., Li, Zeqing, Tang, B., dan Li, Zhaowei, 2021a. 'The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis', , *preprint*, . *Epidemiology*.
- Lou, L., Zhang, H., Li, Zeqing, Tang, B., dan Li, Zhaowei, 2021b. 'The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis', , *preprint*, . *Epidemiology*.
- Murni, I.K., Prawirohartono, E.P., dan Triasih, R., 2021. Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19. *Global Pediatric Health*, **8**: 2333794X2110217.
- Noor, F.M. dan Islam, Md.M., 2020. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. *Journal of Community Health*, **45**: 1270–1282.
- Nugroho, T.E., Mochamat, M., dan Famila, F., 2020. Penggunaan Heparin Dosis Tinggi pada Pasien COVID-19 dengan ARDS dan Hipertensi di Unit Perawatan Intensif (ICU). *JAI (Jurnal Anestesiologi Indonesia)*, **12**: 1–8.
- Oliver, M.E. dan Hinks, T.S.C., 2021. Azithromycin in viral infections. *Reviews in Medical Virology*, **31**: .
- Omrani-Nava, V., Maleki, I., Ahmadi, A., Moosazadeh, M., Hedayatzadeh-Omran, A., Roozbeh, F., dkk., 2020. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. *Hepatitis Monthly*, **20**: .
- PAMKI, 2020. Apakah arti Klinis Nilai Cycle Threshold pada hasil Pemeriksaan real time RT-PCR?
- Pandita, A., Gillani, F.S., Shi, Y., Hardesty, A., McCarthy, M., Aridi, J., dkk., 2021. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. *PLOS ONE*, **16**: e0252411.

- Pandolfi, S., Simonetti, V., Ricevuti, G., dan Chirumbolo, S., 2021. Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients? *Journal of Medical Virology*, **93**: 5704–5706.
- Pardo, J., Shukla, A.M., Chamarthi, G., dan Gupte, A., 2020. The journey of remdesivir: from Ebola to COVID-19. *Drugs in Context*, **9**: 1–9.
- PDPI, P., PAPDI, PERDATIN, dan IDAI, 2021. Revisi Protokol Tatalaksana COVID-19 edisi 3.
- Pemda DIY, 2021. 'Pemerintahan Daerah Istimewa Yogyakarta', . *Pemda DIY*, .
- Pradhan, A. dan Olsson, P.-E., 2020. Sex differences in severity and mortality from COVID-19: are males more vulnerable? *Biology of Sex Differences*, **11**: 53.
- Ramacciotti, E., Barile Agati, L., Calderaro, D., Aguiar, V.C.R., Spyropoulos, A.C., de Oliveira, C.C.C., dkk., 2022. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. *The Lancet*, **399**: 50–59.
- Ramatillah, D.L. dan Isnaini, S., 2021. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. *PLOS ONE*, **16**: e0250147.
- Rezagholidzadeh, A., Khiali, S., Sarbakhsh, P., dan Entezari-Maleki, T., 2021. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. *European Journal of Pharmacology*, **897**: 173926.
- Rico-Caballero, V., Fernández, M., Hurtado, J.C., Marcos, M.A., Cardozo, C., Albiach, L., dkk., 2022. Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. *Infection*, .
- Rusdi, M.S., 2021. Mini Review: Farmakologi pada Corona Virus Disease (Covid-19) **2**: 8.
- Scroggs, S.L.P., Offerdahl, D.K., Flather, D.P., Morris, C.N., Kendall, B.L., Broeckel, R.M., dkk., 2020. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV. *Viruses*, **13**: 8.
- Seaton, R.A., Gibbons, C.L., Cooper, L., Malcolm, W., McKinney, R., Dundas, S., dkk., 2020. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. *Journal of Infection*, **81**: 952–960.
- Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., dkk., 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nature Communications*, **11**: 222.
- Shereen, M.A., Khan, S., Kazmi, A., Bashir, N., dan Siddique, R., 2020. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*, **24**: 91–98.
- Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., dkk., 2020. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology*, **5**: 802.

- Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., dkk., 2021. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infectious Diseases and Therapy*, **10**: 2489–2509.
- Shu, H., He, S., Sun, Y., Lin, C., Lu, Y., Liu, J., dkk., 2021. Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients. *BioMed Research International*, **2021**: 1–9.
- Singhal, T., 2020. A Review of Coronavirus Disease-2019 (COVID-19). *The Indian Journal of Pediatrics*, **87**: 281–286.
- Spinner, C.D., Gottlieb, R.L., Criner, G.J., Arribas López, J.R., Cattelan, A.M., Soriano Viladomiu, A., dkk., 2020. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*, **324**: 1048.
- Spyropoulos, A.C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., dkk., 2021. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. *JAMA Internal Medicine*, **181**: 1612.
- Suranadi, I.W., Sucandra, I.M.A.K., Fatmawati, N.N.D., dan Wisnawa, A.D.F., 2022. A Retrospective Analysis of the Bacterial Infections, Antibiotic Use, and Mortality Predictors of COVID-19 Patients. *International Journal of General Medicine*, **Volume 15**: 3591–3603.
- Tawfik, A., Alzahrani, Abdulrahman, Alharbi, S., Almitairi, J., Alzahrani, Arwa, Alshehri, M.A., dkk., 2022. Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients. *Advances in Virology*, **2022**: 1–7.
- Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., dkk., 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*, **18**: 1023–1026.
- Thiruvengadam, G., Lakshmi, M., dan Ramanujam, R., 2021. A Study of Factors Affecting the Length of Hospital Stay of COVID-19 Patients by Cox-Proportional Hazard Model in a South Indian Tertiary Care Hospital. *Journal of Primary Care & Community Health*, **12**: 215013272110002.
- Trougakos, I.P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O.E., Aivalioti, E., Paraskevis, D., dkk., 2021. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *Journal of Biomedical Science*, **28**: 9.
- Tsai, P.-H., Lai, W.-Y., Lin, Y.-Y., Luo, Y.-H., Lin, Y.-T., Chen, H.-K., dkk., 2021. Clinical manifestation and disease progression in COVID-19 infection. *Journal of the Chinese Medical Association*, **84**: 3–8.
- Uddin, M.S., Millat, Md.S., Baral, P.K., Ferdous, M., Uddin, Md.G., Sarwar, Md.S., dkk., 2021. The protective role of vitamin C in the management of COVID-19: A Review. *Journal of the Egyptian Public Health Association*, **96**: 33.
- Van Vinh Chau, N., Lam, V.T., Dung, N.T., Yen, L.M., Minh, N.N.Q., Hung, L.M., dkk., 2020. The Natural History and Transmission Potential of

- Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Clinical Infectious Diseases*, **71**: 2679–2687.
- Wang, B., Li, R., Lu, Z., dan Huang, Y., 2020. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging*, **12**: 6049–6057.
- Wang, Y., Zhou, F., Zhang, D., Zhao, J., Du, R., Hu, Y., dkk., 2020. 'Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe Pneumonia caused by COVID-19 virus Infection: study protocol for a Phase 3 Randomized, Double-blind, Placebo-controlled, Multicentre trial', *preprint*, . In Review.
- Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., dkk., 2020. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*, **584**: 430–436.
- Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, Xing, Xu, S., dkk., 2020. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*, **180**: 934.
- Xu, K., Chen, Y., Yuan, J., Yi, P., Ding, C., Wu, W., dkk., 2020. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases*, **71**: 799–806.
- Yasuda, H., Mayumi, T., dan Okano, H., 2022. Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. *Infection*, .
- Yavuz, S.Ş. dan Ünal, S., n.d. Antiviral treatment of COVID-19. *Turk J Med Sci*, **9**.
- Zhang, T., Wu, Q., dan Zhang, Z., 2020. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology*, **30**: 1346–1351.e2.
- Zheng, X., Chen, J., Deng, L., Fang, Z., Cheng, G., ye, ji, dkk., 2021. Risk factors for COVID-19 severity and their association with viral release: A retrospective cohort study. *J Med Virol*. 2021;93:952–961., .
- Zhu, N., Yang, B., Shi, W., Ma, X., Gao, G.F., Phil, D., dkk., 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The new england journal of medicine*, **7**.



UNIVERSITAS
GADJAH MADA

Perbandingan Efektivitas Dan Keamanan Terapi Antiviral Favipiravir Dan Remdesivir Pada Pasien Covid-19 Di RSUP Dr. Sardjito Yogyakarta

NOVA SATRIYANI, Dr. apt. Fita Rahmawati, Sp. FRS; Prof. Dra. apt Tri Murti Andayani.Sp. FRS., PhD

Universitas Gadjah Mada, 2022 | Diunduh dari <http://etd.repository.ugm.ac.id/>